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The therapeutic utility of siRNAs is limited by the
requirement for complex formulations to deliver
them to tissues. If potent single-stranded RNAs
could be identified, they would provide a simpler
path to pharmacological agents. Here, we describe
single-stranded siRNAs (ss-siRNAs) that silence
gene expression in animals absent lipid formulation.
Effective ss-siRNAs were identified by iterative
design by determining structure-activity relation-
ships correlating chemically modified single strands
and Argonaute 2 (AGO2) activities, potency in cells,
nuclease stability, and pharmacokinetics. We find
that the passenger strand is not necessary for potent
gene silencing. The guide-strand activity requires
AGO2, demonstrating action through the RNAi
pathway. ss-siRNA action requires a 50 phosphate
to achieve activity in vivo, and we developed a meta-
bolically stable 50-(E)-vinylphosphonate (50-VP) with
conformation and sterioelectronic properties similar
to the natural phosphate. Identification of potent
ss-siRNAs offers an additional option for RNAi
therapeutics and an alternate perspective on RNAi
mechanism.INTRODUCTION
RNA interference (RNAi) is a mechanism by which double-
stranded RNA triggers the loss of RNA of homologous sequence
(Fire et al., 1998). Long double-strand RNAs are processed by
the double-strand endonuclease Dicer into short RNA duplexes
ranging from 21 to 23 nucleotides in length (Bernstein et al.,
2001). The double-strand RNA-binding proteins Dicer and HIV-1
trans-activating response RNA-binding protein (TRBP) transfer
the short RNA duplexes to the RNA-induced silencing complex
(RISC) (Chendrimada et al., 2005). The antisense strand of the
short RNA duplexes binds to the RISC endonuclease Argonaute2 (Ago2), which then cleaves the target mRNA (Elbashir et al.,
2001; Tomari et al., 2004; Nyka¨nen et al., 2001; Meister et al.,
2004; Rand et al., 2004; Song et al., 2004; Rivas et al., 2005).
Synthetic short interfering RNA duplexes (siRNA) have been
shown to potently reduce complementary mRNA in cells by acti-
vating the RISC mechanism and show promise as therapeutic
agents (Elbashir et al., 2001; Caplen, 2003). However, in their
current state, the therapeutic utility of siRNA is limited by the
requirement for complex lipid formulations to deliver siRNA to
peripheral tissues (Vaishnaw et al., 2010). Lipid formulations of
oligonucleotides and polynucleotides are complex, expensive
to manufacture, and shown to be associated with proinflamma-
tory toxicities (Tao et al., 2011). In contrast, single-strand anti-
sense oligonucleotides do not require special formulations to
distribute to peripheral tissues (Bennett and Swayze, 2010).
Interestingly, although siRNAs are double-stranded structures,
human Ago2 has been shown to bind only short single-stranded
RNAs (ssRNA) (Lima et al., 2009a; Rivas et al., 2005). In addition,
human Dicer has been shown to bind short ssRNAs with
affinities comparable to siRNAs, suggesting that ssRNAs might
be capable of activating the RNAi pathway (Lima et al., 2009b).
ssRNAs were shown early on to reduce complementary tar-
get RNA in cells, although the reported activities of the ssRNAs
were poor compared to double-stranded siRNA (Martinez
et al., 2002; Schwarz et al., 2002; Wu et al., 1998). The metabolic
instability of the ssRNAs compared to double-stranded siRNAs
likely contributed to the poor activities observed for the ssRNAs
(Braasch et al., 2003, Wu et al., 1998). Chemical modifications
predicted to enhance the nuclease stability of ssRNAs have
been evaluated in cells and animals, and many of the modifica-
tions and motifs enlisted were patterned after successful siRNA
motifs (Holen et al., 2003; Hall et al., 2004; Haringsma et al.,
2012; Prakash et al., 2005; Dande et al., 2006; Allerson et al.,
2005). These modified ssRNAs were significantly less potent
than siRNAs, suggesting that the structure-activity relationships
for ssRNA differ from siRNAs (Holen et al., 2003; Hall et al., 2004;
Haringsma et al., 2012). In addition, absent lipid formulations, the
ssRNAs were inactive in animals, suggesting that the modified
ssRNAs exhibited insufficient metabolic stability and other
necessary pharmacokinetic properties to support activity (Har-
ingsma et al., 2012). Taken together, these results suggest thatCell 150, 883–894, August 31, 2012 ª2012 Elsevier Inc. 883
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Figure 1. Modified Nucleic Acid Composition, In Vitro Potencies, and Half-Lives of Potent ss-siRNAs
(A) Configuration of the optimized chemically modified ss-siRNA includes:metabolically stable 50 phosphonate analog (I); 20-MOE-modified 50-terminal nucleotide
for protection from 50 exonuclease activity (II); alternating 20-F and 20-OMemotifs with contiguous PSmodifications at the 30 pole and alternating PS and POmotifs
at the 50 pole of the ss-siRNA for protection from endonuclease activity (III); 20-MOE-modified adenosine dinucleotide at the 30 terminus for protection from 30
exonuclease activity and enhanced potency (IV); and C16 modification for enhanced tissue distribution (V). The color coding of the modified nucleotides is as
described in (B). Following either subcutaneous or intravenous administration, the ss-siRNA distributed to peripheral tissues and engaged the RNAi mechanism
to degrade the target mRNA.
(B) Nucleotide modifications include: phosphorothioate (PS), 20-fluororibose (green, 20-F), 20-methoxyribose (blue, 20-OMe), 20-methoxyethylribose (orange,
20-MOE), 50-methylenephosphonate (red, 50-MP), 50-(E)-vinyl-phosphonate (red, 50-VP), C10 (TC10), and C16 (TC16).
(C) Nucleotidemodifications are described in (B). The siRNAswere prepared using a complementary RNA sense strand (50-AAGUAAGGACCAGAGACAA-30). The
in vitro potencies (IC50) correspond to the ss-siRNA or siRNA concentration, resulting in 50%reduction of the PTEN mRNA level compared to lipid-only treated
cells. Data are represented as mean ± SD. The metabolic half-lives (t1/2) of the ss-siRNAs are defined as the incubation time in primary hepatocyte homogenates,
resulting in 50% loss of the full-length ss-siRNA. ND, not determined.
See also Table S1 and Figures 1 and 5.to develop potent ssRNA therapeutics requires: (1) the iden-
tification of chemical modifications that enhance the meta-
bolic stability and other pharmacokinetic properties of the
ssRNAs and (2) interactions with key components of the RISC
mechanism.
In this study, we evaluated the abilities of chemically modi-
fied single-stranded short interfering RNA (ss-siRNA) molecules
to bind to human Ago2 and support cleavage activity (Fig-
ure 1A). Having defined the sites that tolerate modifications884 Cell 150, 883–894, August 31, 2012 ª2012 Elsevier Inc.and the structure-activity relationships of productive interac-
tions with Ago2, we then evaluated the modified ss-siRNAs
for stability, other pharmacokinetic properties, and activity in
cultured cells. Next, the optimized ss-siRNAs were evaluated
in animals. We demonstrated that optimized ss-siRNAs could
be designed to reduce multiple targets and could work in
the liver and other tissues after subcutaneous or intravenous
dosing and confirmed that the observed activities were RISC
mediated.
Figure 2. Ago2 Cleavage Activities of
Chemically Modified ss-siRNAs
(A) Scheme for cleavage of ss-siRNA by Ago2. The
ss-siRNAwas bound to the enzyme prior to adding
the target RNA. Ago2 containing the ss-siRNA
was incubated with the 32P-labeled target RNA.
Double-stranded siRNAs were not tested, as they
do not bind recombinant human Ago2.
(B) Relative recombinant human Ago2 cleavage
activity for various ss-siRNAs. Cleavage activities
of the ss-siRNAs are reported as a ratio of the
cleavage activity observed for the unmodified
ss-siRNA1. Data are represented as mean ± SD.
(C) PAGE analysis of 32P-labeled 40 nucleotide
target RNA and human Ago2 cleavage products
(red arrow). The position of the Ago2 cleavage site
(red arrow) in the target RNA (black sequence) is
shown relative to the ss-siRNA (gray sequence).RESULTS
Identification of Potent and Metabolically Stable
ss-siRNAs
To identify potent ss-siRNAmolecules, we determined themeta-
bolic stabilities of the ss-siRNAs in cell homogenates and the
potencies of the ss-siRNAs and corresponding siRNAs in cells.
We also measured cleavage activities of purified recombinant
human Ago2 bound to the ss-siRNAs in order to better under-
stand the structure-activity relationships between the ss-siRNA
and Ago2. Human Ago2 cleavage activities were not determined
for siRNAs, as the enzyme has been shown not to bind double-
stranded siRNA (Figure 2A) (Lima et al., 2009a; Rivas et al.,
2005).
First, we evaluated ss-siRNAs containing uniform phosphoro-
thioate intranucleotide linkages (PS), as phosphorothioates have
been shown to enhance both metabolic stability and pharmaco-
kinetic properties of single-stranded antisense oligonucleotides
(Figure 1B) (Graham et al., 1998; Graham et al., 2001). The
uniform PS substitutions enhanced the metabolic stability of
the ss-siRNAs compared to the unmodified ss-siRNA 1, and
in the case of the 20-F ss-siRNA 3, the half-life in hepatocyte
homogenates exceeded 6 hr (Figure 1C). Unfortunately, the
ss-siRNAs containing uniform PS substitutions (2 and 3) were
inactive in cells and exhibited reduced human Ago2 cleavage
activities (Figures 1C, 2B, and 2C). The siRNA analogs of the
ss-siRNAs 2 and 3 were also less potent in vitro when compared
to the unmodified ss-siRNA 1 (Figure 1C).
A survey of the preferred sites for PS substitutions in the ss-
siRNA identified an active motif consisting of seven contiguous
PS substitutions positioned at the 30 pole of the ss-siRNA
(4 and 5) (Figure 1C). The siRNAs (4 and 5) were also more active
compared to the uniform PS-modified siRNAs (2 and 3) (Fig-
ure 1C). Similarly, enhanced human Ago2 cleavage activities
were observed for ss-siRNAs 4 and5 compared to the ss-siRNAsCell 150, 883–8942 and 3 (Figures 2 B and 2C). The ss-
siRNA containing the uniform 20-F and
seven PS motif (5) exhibited the greatest
in vitro potency (IC50 of 19nM) (Figure 1C).To further enhance the potency of the ss-siRNA 5, we turned
our attention to the 30 terminus of the compound. Previous
reports indicated that single-stranded 30-dinucleotide overhangs
containing purine residues enhance the in vitro potencies of
siRNAs presumably by interacting with human Dicer (Rose
et al., 2005; Lima et al., 2009b).
To determine whether a similar dinucleotide composition at
the 30 terminus would enhance the in vitro potency of ss-siRNAs,
two adenosine nucleotides were appended to the 30 terminus of
the ss-siRNA containing the uniform 20-F, seven PS ss-siRNA
motif (6) (Figure 1C). A 4-fold increase in potency was observed
for the ss-siRNA 6 containing the additional 20-MOE adenosine
dinucleotide compared to the ss-siRNA 5 without the additional
30-dinucleotide (Figure 1C). Importantly, similar human Ago2
cleavage activities were observed for the ss-siRNAs 5 and 6,
suggesting that Ago2 was not contributing significantly to the
enhanced potency observed for the ss-siRNA 6 (Figures 2B
and 2C).
Similar half-lives were observed for the ss-siRNAs 5 and 6 in
hepatocyte homogenates, suggesting that the 20-MOE modified
adenosine dinucleotide had little effect on nuclease stability of
these ss-siRNAs (Figure 1C). The LC-MS analysis showed that
the majority of the nuclease degradation occurred in the non-
phosphorothioate region, i.e., the 50 pole, of the ss-siRNA 5 (Fig-
ure 3A). These data suggest that, although the seven contiguous
phosphorothioates were sufficient to protect the 30 pole of the
ss-siRNA from nuclease degradation in hepatocyte homoge-
nates, additional chemical modification of the 50 pole of the ss-
siRNA was required to further improve the metabolic stability
of the ss-siRNA.
An alternating 20-F and 20-methoxy ribonucleotide (20-OMe)
motif was employed, as similar motifs were reported to enhance
the potency and metabolic stability of siRNAs (Figure 1B) (Aller-
son et al., 2005; Dande et al., 2006; Prakash et al., 2005). Addi-
tional phosphorothioate substitutions were also included along, August 31, 2012 ª2012 Elsevier Inc. 885
Figure 3. Identification of ss-siRNA Metabolites Extracted from Hepatocyte Homogenates or Mouse Liver
(A) Liquid chromatography-tandem mass spectrometry (LC-MS) analysis of the ss-siRNA 5 extracted from hepatocyte homogenates 1 hr posttreatment.
(B–E) LC-MS of ss-siRNAs 7 (B), 8 (C), 26 (D), and 27 (E) extracted from mouse liver 48 hr posttreatment. The liquid chromatography profiles show the relative
abundance of the metabolites identified by mass spectrometry compared to the internal standard (Int. Std.). Numbered arrows indicate the position of degra-
dation sites in the ss-siRNA in relationship to the corresponding peaks from the liquid chromatography profile.with either a 20-OMe (7) or 20-MOE (8) at the 50 terminus. A sig-
nificant increase in metabolic stability was observed for the
ss-siRNAs 7 and 8 with half-lives in hepatocyte homogenates
greater than 8 hr (Figure 1C). An 2-fold increase in potency
was observed for the ss-siRNAs 7 and 8 compared to the
ss-siRNA 6 (Figure 1C). The alternating 20-F and 20-OMe motif
appeared to be well tolerated by human Ago2, as similar
cleavage activities were observed for the ss-siRNAs 7 and 8
compared to the unmodified ss-siRNA 1 (Figure 2B and C). Simi-
larly, the in vitro potencies observed for the siRNAs 7 and 8 were
comparable to the unmodified siRNA 1 (Figure 1C). Importantly,
we identified ss-siRNAs that are both potent and metabolically
stable in vitro.
ss-siRNA Activity Is Ago2 Dependent
To determine whether ss-siRNA-mediated reduction of the tar-
getmRNA in cells was the result of Ago2 cleavage, we performed
50 rapid amplification of cDNA ends (50-RACE) to map the
cleavage site on the PTEN mRNA from lipid-only-treated cells
and cells treated with the ss-siRNA 8 (Figure 4A). Consistent
with the Ago2 cleavage mechanism, sequencing analysis of
the 50-RACE products revealed a single cleavage site positioned
at the phosphodiester bond bridging the ribonucleotides oppos-
ing the tenth and eleventh nucleotide from the 50 terminus of886 Cell 150, 883–894, August 31, 2012 ª2012 Elsevier Inc.the ss-siRNA (Figure 4A). No cleavage products were observed
for the lipid-only-treated cells (data not shown). Taken together,
these data suggest that ss-siRNAs activate Ago2 to degrade the
target mRNA in a manner similar to that reported for siRNAs
(Elbashir et al., 2001; Tomari et al., 2004; Nyka¨nen et al., 2001;
Meister et al., 2004; Rand et al., 2004; Song et al., 2004; Rivas
et al., 2005).
To confirm that ss-siRNAs function through an Ago2 mecha-
nism, we measured the potency of ss-siRNA 8 and correspond-
ing siRNA in wild-type and Ago2 knockout mouse embryonic
fibroblast (MEF) cells (Figure 4C). Both the ss-siRNA 8 and siRNA
showed dose-dependent reduction of the PTEN mRNA in the
wild-type MEF cells (Figure 4C). However, no PTEN mRNA
reduction was observed for either the 8 ss-siRNA or siRNA in
the Ago2 knockout cells, suggesting that the activities of ss-
siRNA and siRNA are Ago2 dependent (Figure 4C).
The 50 Phosphate Is Required for ss-siRNA Activity,
but Not for siRNA Activity
Previous reports suggest that the 50 phosphate is important for
siRNA and ss-siRNA activity and enhance the binding affinity
of ss-siRNAs to human Ago2 (Chen et al., 2008; Haringsma
et al., 2012; Lima et al., 2009a). To evaluate the role of the 50
phosphate in the activities of the ss-siRNAs, we determined
Figure 4. ss-siRNA Activity Is Ago2 Dependent and Requires a 50 Phosphate
(A) The position of the cleavage site within the PTEN mRNA from cells treated with ss-siRNA 8 was determined using 50-RACE. Sequencing results are shown in
the top panel. The red sequence corresponds to the 50-RACE adaptor and the black sequence to the downstream cleavage product of the PTEN mRNA. The
position of cleavage is identified as the junction between the 50-RACE adaptor and the PTENmRNA (red line). The sequence below shows the position of cleavage
site (arrow) on the PTEN mRNA (black sequence) in relation to the hybridization site for the ss-siRNA (gray sequence).
(B) 50-terminal modifications include: 50 phosphate (50-P), 50 hydroxyl (50-OH), 50 methoxy (50-OMe), 50 deoxy (50-H), and 50 fluoro (50-F). The siRNAs were prepared
and the in vitro potencies in HeLa cells reported as in Figure 1. ND, not determined.
(C) Dose-dependent reduction of PTEN mRNA from wild-type (gold) and Ago2 knockout (blue) mouse embryonic fibroblast cells (MEF) transfected with the
ss-siRNA 8 (solid circle) or corresponding siRNA (solid square). PTEN mRNA levels are reported as a percentage of the PTEN mRNA levels for the lipid-only-
treated cells.
(D) Human Ago2 cleavage activities of ss-siRNA are reported as described in Figure 2.
See also Table S1 and Figures S2, S3, and S4. Data are represented as mean ± SD.the Ago2 cleavage activities of ss-siRNAs and corresponding
siRNAs containing a 50-hydroxyl (50-OH) moiety (Figures 4B
and 4D). The ss-siRNAs containing the 50-OH (9 through 13) ex-hibited human Ago2 cleavage activities that were 2- to 4-fold
lower than the corresponding ss-siRNAs containing a 50-phos-
phate (1, 4, 5, and 8) (Figures 1C and 4B). A similar 2- to 4-foldCell 150, 883–894, August 31, 2012 ª2012 Elsevier Inc. 887
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Figure 5. Potency of ss-siRNA in Hepato-
cytes and Efficacy in Mice
(A) The in vitro potencies (IC50) of the ss-siRNAs
targeting PTEN (I), Factor VII (II), or ApoCIII (III)
mRNAs were determined using primary hepato-
cytes.
(B) The PTEN mRNA levels from the livers of
mice treated with either 300 mg/kg (back bars) or
100mg/kg (red bars) of the ss-siRNAs are reported
as a percentage of the PTEN mRNA from the
saline-treated group. The Factor VII (blue bar) or
ApoCIII (green bar) mRNA levels from the livers of
mice treated with 300 mg/kg of the Factor VII or
ApoCIII ss-siRNAs, respectively.
(C) Liver concentrations of the PTEN ss-siRNAs
were measured from mice treated with either
300 mg/kg (black bars) or 100 mg/kg (red bars).
Liver concentrations of the Factor VII (blue bar) or
ApoCIII (green bar) ss-siRNAs were measured
from mice treated with 300 mg/kg.
ND and I indicate not determined and inactive,
respectively. Data are represented as mean ± SD.
See also Tables S1 and S2.reduction in in vitro potency was observed for the siRNAs 9
through 13 compared to siRNAs 1, 4, 5, and 8 (Figures 1C and
4B). No reduction of PTEN mRNA was observed in cells treated
with the modified ss-siRNAs 10 through 13, suggesting that the
50 phosphate is required for ss-siRNA activity, but not for siRNA
activity, in cells (Figure 4B).
Chen et al. used 50-methoxy (50-OMe)-modified siRNA to
conclude that the in vitro activities of siRNAs containing a 50
hydroxyl might be due to the 50 phosphorylation of the siRNA
in the cells, as siRNA containing 50-OMe modification, which is
refractory to phosphorylation, was inactive (Chen et al., 2008).
To determine whether ss-siRNA behave in a similar manner,
we designed ss-siRNAs 14 and 15 containing the 50-OMe modi-
fication, and consistent with their results, the ss-siRNAs and
siRNAs 14 and 15 were significantly less potent in vitro (Figures
4B, S1, and S2). However, the ss-siRNAs 14 and 15 were also
inactive in the human Ago2 cleavage assay (Figure 4D). Taken
together, our results suggest that the loss in activity observed
for the siRNA containing the 50-OMe is not due to the inability
of the siRNA to be phosphorylated in the cell but that the
50-OMe modification most likely interferes with the interaction
between the ss-siRNA and Ago2 (Figures 4B and 4D).
Next, we evaluated other 50 modifications that are refractory
to phosphorylation (e.g., 50-fluoro [50-F] or 50-deoxy [50-H]) (Fig-
ures 4B, S1, S3, and S4). The human Ago2 cleavage activities888 Cell 150, 883–894, August 31, 2012 ª2012 Elsevier Inc.observed for the ss-siRNAs containing
the 50-F (16 and 17) and 50-H (18 and 19)
moieties were comparable to the corre-
sponding ss-siRNAs containing the 50
hydroxyl (9 and 13), suggesting that the
50-F and 50-H modifications do not inter-
fere with the interaction between the ss-
siRNA and Ago2 (Figure 4D). Importantly,
unlike the siRNAs containing the 50-OMe
modification (14 and 15), the siRNAs con-taining the 50-F (16 and 17) and 50-H (18 and 19) were significantly
more potent even though these modifications are also refractory
to phosphorylation (Figure 4B). On the other hand, the modified
ss-siRNAs containing either the 50-F (17) or 50-H (19) were inac-
tive in vitro (Figure 4B). Taken together, these results unequivo-
cally demonstrate that the 50 phosphate is required for ss-siRNA
activity, but not for siRNA activity, in cells.
50 Phosphate Is a Critical Determinant for ss-siRNA
Activity In Vivo
The ss-siRNAs exhibiting the greatest in vitro potency and meta-
bolic stability (7 and 8) were evaluated in primary hepatocytes
and in mice (Figures 5A and 5B). In addition, the ss-siRNAs
were extracted from the liver to determine the total liver concen-
trations of the compounds and to identify any metabolites
(Figures 3B, 3C, and 5C).
No reduction in the PTEN mRNA levels was observed in mice
treated with the ss-siRNAs 7 and 8 compared to the control mice
(Figure 5B). Analysis of the ss-siRNAs extracted from the mouse
liver revealed no intact compound (Figure 3B and C). The pre-
dominant metabolite observed for the ss-siRNA 7 consisted of
the 30 pole of the ss-siRNA containing the nine contiguous phos-
phorothioates (Figure 3B). Conversely, the predominant metab-
olite identified for the ss-siRNA 8 consisted of the full-length
compound absent the 50 phosphate, and studies with shorter
treatment times indicated that the compound was completely
dephosphorylated in as few as 6 hr (Figure 3C and data not
shown). Importantly, these results indicated that the 50-terminal
20-MOE and alternating PS substitutions at the 50 pole signifi-
cantly enhanced the metabolic stability of the ss-siRNA 8
compared to the ss-siRNA 7 in vivo (Figures 3B and 3C). In addi-
tion, the lack of in vivo activity observed for the ss-siRNA 8 was
consistent with our observations that the 50 phosphate is
required for ss-siRNA activity. These data suggest that hepato-
cyte homogenates appear to be poor predictors of themetabolic
stability and phosphatase activity in animals, as no measurable
difference in metabolic stability was observed for the 7 and 8
ss-siRNAs in homogenates (Figure 1C).
Identification of ss-siRNA Exhibiting Robust Activity
in Animals via RNAi
Our in vitro and mechanistic studies showed that ss-siRNA
activity requires a phosphate at the 50 terminus (Figures 4B
and 4D). Given that the modified ss-siRNA extracted from liver
was rapidly dephosphorylated, we concluded that the loss of
the phosphate was responsible for the observed lack of in vivo
activity (Figures 3B, 3C, 5B). This prompted the search for 50
phosphate analogs that are stable in animals and resulted
in the identification of the 50-methylenephosphonate (50-MP)
(Figures 1B and S1). This modification contains a phosphorous
carbon bond instead of the phosphorous oxygen bond found
in natural phosphates, and as there are no known natural
enzymes capable of cleaving the phosphorous carbon bond,
the 50-MP modification was predicted to be stable in animals.
The ss-siRNA containing the 50-MP modification (20) was active
in mice exhibiting a 22% reduction of the PTEN mRNA in liver
(Figure 5B). The LC-MS analysis of the ss-siRNA 20 extracted
from liver showed that the compound contained the 50-MP
moiety (Figure 3D). Importantly, these results demonstrated the
reduction of target mRNA in vivo using an ss-siRNA adminis-
tered without lipid formulation or sense strand. In addition, these
results further demonstrated the requirement of the 50 phosphate
for ss-siRNA activity in both cells and animals.
To ensure that the activities observed for the 50-MP ss-siRNA
were not unique to this sequence, two additional target sites
within the PTEN mRNA (22 and 25) were identified (Figure 5A).
The 50-MP analogs of these ss-siRNAs (23 and 26) exhibited
comparable and greater in vivo activity, respectively (Figure 5B).
Similar liver concentrations were observed for the ss-siRNAs 20,
23, and 26 (e.g., 220, 250, and 210 mg/g, respectively), suggest-
ing that the greater in vivo activity observed for the ss-siRNA 26
was not due to differences in the pharmacokinetic properties of
the compounds (Figure 5C). Consistent with the in vivo activities,
the ss-siRNA 26 exhibited a 2-fold greater potency in vitro
compared to the ss-siRNAs 20 and 23 (Figure 5A).
The reduced in vitro potency observed for the 50-MP modified
ss-siRNAs compared to the corresponding ss-siRNAs contain-
ing a 50 phosphate may have been due to conformational and/
or sterioelectronic differences between the methylenephospho-
nate and natural phosphate (Figure 5A). A survey of methylene-
phosphonate analogs identified the 50-(E)-vinylphosphonate
(50-VP), which contains a double bond between 50 and 60 carbon
in a trans configuration producing a conformation and sterioelec-tronic properties closer to the natural phosphate (Figures 1B
and S1).
The ss-siRNAs 24 and 27 containing the 50-VP modification
exhibited comparable potencies to the ss-siRNA containing
the 50 phosphate (25) and 3- to 7-fold greater potency in vitro
compared to the ss-siRNAs 23 and 26 containing the 50-MP
(Figure 5A). Consistent with the increased in vitro potency, the
ss-siRNAs 24 and 27 were also more effective in vivo than
the 50-MP ss-siRNAs (Figure 5B). Again, LC-MS analysis of the
ss-siRNA 27 extracted from liver showed that the compound
contained the 50-VP moiety and similar liver concentrations
compared to the 50-MP modified ss-siRNAs, suggesting that
the enhanced in vivo activities observed for the 50-VP ss-siRNAs
was not due to differences in pharmacokinetic properties of the
compounds (Figures 3E and 5C). Next, we determined the in vivo
potency of ss-siRNA 27 (Figure 6B). The ss-siRNA 27 reduced
the PTEN mRNA in a dose-dependent manner (Figure 6B).
To demonstrate that the in vivo activities observed for the ss-
siRNA 27 involved an Ago2mechanism, 50-RACEwas performed
on the RNA extracted from the livers of the mice treated with the
ss-siRNA 27 (Figure 6A). Similar to the in vitro 50-RACE results,
sequencing analysis of the 50-RACE products from mice treated
with the ss-siRNA 27 showed that the predominant cleavage
product within the PTEN mRNA was consistent with the Ago2
cleavage mechanism, and no cleavage products were observed
for the control mice (Figure 6A).
Next, we investigated the duration of action and elimination
half-life of the ss-siRNA 27 in mouse liver (Figures 6C and 6D).
The in vivo efficacy of the ss-siRNA 27 over time correlated with
the concentrations of the ss-siRNA in the liver, with an 60%
reduction in PTENmRNAobservedby 24 hr. Thiswasmaintained
for about 3 days, after which the ss-siRNA concentration in the
liver declined, as did the observed activity (Figures 6C and 6D).
ss-siRNA In Vivo Activity Is General for Other Targets
We evaluated the in vitro and in vivo activities of the 50-VP modi-
fied ss-siRNAs targeting factor VII and ApoCIII mRNAs (Fig-
ure 5A). Potent 50-VP ss-siRNA sequences targeting Factor VII
(31) and ApoCIII (32) mRNAs identified in mouse hepatocytes
were tested in mice and showed a >50% reduction of their
respective target mRNAs in liver compared to the control mice
(Figures 5A and 5B). The additional targets also provided the
opportunity to access the target specificity of the ss-siRNAs.
Specifically, we measured the PTEN and Factor VII mRNA levels
for the mice treated with the ApoCIII ss-siRNA, the PTEN and
ApoCIII mRNA levels for the mice treated with the Factor VII
ss-siRNAs, and the ApoCIII and Factor VII mRNA levels for the
PTEN ss-siRNA treated mice (Figure 6E). The ss-siRNAs
reduced the levels of their respective target mRNAs, but not
the off-target mRNAs (Figure 6E). A scrambled sequence control
ss-siRNA (30) was also evaluated, exhibiting no reduction on
PTEN mRNA in cells and a less <10% percent reduction of
PTEN mRNA in mice (Figures 5A and 5B).
Lipid Modification Improves ss-siRNA Potency in
Animals
Previous studies have shown that adding lipophilic modifications
can enhance distribution to the liver and cellular uptake (Crooke,Cell 150, 883–894, August 31, 2012 ª2012 Elsevier Inc. 889
Figure 6. In Vivo Activities of Modified
ss-siRNAs following Single-Dose Adminis-
tration
(A) The position of the cleavage site within the
PTEN mRNA from mice treated with the ss-siRNA
27 was determined using 50-RACE. The procedure
and interpretation of the results are as described in
Figure 4A.
(B) Dose-dependent reduction of PTEN mRNA
from liver of mice (n = 4) treated with a single dose
of either ss-siRNAs 27 (green bars) or 29 (purple
bars) administered subcutaneously and sacrificed
48 hr posttreatment.
(C and D) Duration of action (C) and tissue half-life
(D) of the ss-siRNA 27 in mouse liver. Mice (n = 4)
were treated with 100 mg/kg ss-siRNA 27 by
subcutaneous administration and sacrificed at 1,
2, 3, 10, and 30 days posttreatment. Liver PTEN
mRNA levels (C) are reported as a percentage of
the PTEN mRNA levels for the saline-treated
control group and the ss-siRNA 27 concentrations
in the liver (D) for each time point.
(E) On- and off-target activities from livers of the
mice treated with 300 mg/kg of the ss-siRNAs
targeting PTEN (27), Factor VII (31), or ApoCIII (32).
The PTEN (gold bar), Factor VII (tan bar), and
ApoCIII (peach bar) mRNA levels were determined
for all ss-siRNA-treated mice and reported as
a percentage of the respective mRNAs levels from
the saline-treated group.
(F) Reduction of PTEN mRNA from the peripheral
tissues of mice treated with 100 mg/kg of the
ss-siRNAs 27 or 29. The PTEN mRNA levels from
kidney (dark blue), quadriceps (medium blue), lung
(light blue), and fat (light green).
Data are represented as mean ± SD.2008). We evaluated a number of lipophilic modifications at
various positions on the ss-siRNA and identified the C10 and
C16 modification, which when positioned at the eighth nucleo-
tide from the 50 terminus of the 50-VP-modified ss-siRNA (28
and 29, respectively), resulted in in vitro potencies comparable
to the unconjugated ss-siRNA (27) (Figures 1B, 5A, S1, and
S5). In the case of the ss-siRNA 28 containing the C10 adduct,
neither an increase in the liver concentrations of the ss-siRNA
nor an increase in in vivo efficacy was observed compared to
the unconjugated ss-siRNA 27 (Figures 5B and 5C). In contrast,
the ss-siRNA containing the C16 modification (29) exhibited
greater in vivo activity and liver concentration compared to
the unconjugated ss-siRNA (Figures 5B and 5C). Greater activity
was also observed for the ss-siRNA 29 containing the C16
modification in quadriceps, lung, and fat tissues compared to890 Cell 150, 883–894, August 31, 2012 ª2012 Elsevier Inc.the ss-siRNA 27, suggesting that the
C16 adduct appeared to enhance the dis-
tribution of the ss-siRNA to tissues other
than the liver (Figure 6F).
Next, we determined the in vivo
potency of the C16 ss-siRNA (29) (Fig-
ure 6B). The ss-siRNA 29 reduced the
PTEN mRNA in a dose-dependent man-
ner and exhibited a 3-fold greater in vivopotency compared to the unconjugated ss-siRNA 27 (Figure 6B).
The increase in potency observed for the C16 ss-siRNA (29)
compared to ss-siRNA (27) is more remarkable given that the
in vitro potency of the ss-siRNA 29 was 10-fold lower compared
to the ss-siRNA 27 (Figure 5A). Further increase in potency was
observed for the ss-siRNA 29 following a longer-term dosing
regime of twice a week for 3 weeks using either subcutaneous
or intravenous administration (Figure 7A). Comparable potencies
were observed for the ss-siRNA 29 using either route of admin-
istration (Figure 7A).
Finally, throughout the course of the in vivo studies, the
animals were monitored for signs of ss-siRNA-associated toxic-
ities. No adverse effects, such as elevated transaminase, bili-
rubin, cholesterol, and triglyceride levels or increased spleen
and liver weights, were observed (Figures 7B and 7C).
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Figure 7. In Vivo Activities ofModified ss-siRNAs followingMultiple-
Dose Administration
(A) Dose-dependent reduction of PTENmRNA from liver of mice (n = 4) treated
with ss-siRNA 29 by either subcutaneous (red bars, SQ) or intravenous (blue
bars, IV) administration. The ss-siRNA was dosed twice a week for 3 weeks,
and the doses reported are per injection.
(B and C) Aminotransferase (B) and bilirubin (C) levels from the mice described
in (A) treated with the ss-siRNA 29 by either subcutaneous (red bars) or
intravenous (blue bars) administration.
Data are represented as mean ± SD.DISCUSSION
In this study, we identified single-strand siRNAs that reduce
target mRNA in animals absent lipid formulation. We show that
the ss-siRNA reduced the target mRNA both in vitro and in vivo
by recruiting the RISC endoribonuclease Ago2 to cleave the
mRNA (Figures 4A, 4C, and 6A). Importantly, we show that
the 50 phosphate is required for ss-siRNA activity, but not for
siRNA activity, and as a result, metabolically stable 50 phosphate
analogs are necessary for ss-siRNA activity in vivo (Figures 4B
and 4C). In fact, the structure-activity relationships observed
for siRNAs differ sufficiently from ss-siRNAs, as to provide littleguidance in designing effective ss-siRNAs (Figures 1C and 4B).
Nor was the use of cellular homogenates or serum predictive
of the robust nuclease and phosphatase activities found in
animals (Figure 1C). In the end, identification of the optimum
ss-siRNA required understanding the structure-activity relation-
ships of human Ago2 activity, intrinsic potency, nuclease sta-
bility, and pharmacokinetics of the ss-siRNA.
ss-siRNAs Activate RNAi in Cells and Animals
Our results demonstrate that the sense strand of siRNA is
not required to activate RNAi in cells or animals (Figures 1C,
5A, and 5B). Ultimately, the RNAi mechanism requires the
removal of the sense strand in order for the antisense strand of
the siRNA to bind the mRNA target. Previous reports suggest
that this occurs prior to binding human Ago2, as the enzyme
was shown to bind single-stranded oligonucleotides, but not
double-stranded oligonucleotides, and human Ago2 cleavage
activity was observed only when the antisense strand was
allowed to bind to the enzyme prior to the mRNA (Figure 2A)
(Lima et al., 2009a).
As a component of the RISC-loading complex, Dicer is
believed to participate in the translocation of siRNA to the
RISC complex, which contains Ago2 (Chendrimada et al.,
2005). Human Dicer has been shown to bind ss-siRNAs-contain-
ing purines at the 30 terminus with affinities comparable to
double-stranded siRNAs (Lima et al., 2009b; Kini and Walton,
2007; Macrae et al., 2006). Consistent with these observations,
a 4-fold increase in potency was observed for ss-siRNAs con-
taining an adenosine dinucleotide at the 30 terminus (Figure 1C).
Importantly, no statistically significant increase in human Ago2
cleavage activity was observed for the ss-siRNA containing the
additional adenosine dinucleotide, suggesting that Ago2 was
not contributing to the enhanced potency and that other factors
(e.g., human Dicer) may be involved. Taken together, these
results suggest that identifying additional contributors to the
activities of ss-siRNAs and optimizing ss-siRNAs to better in-
teract with these factors should further enhance the potencies
of ss-siRNAs.
A Metabolically Stable 50 Phosphate Is Required for
ss-siRNA Activity In Vivo
The identification of a potent and metabolically stable 50 phos-
phate was paramount to achieving ss-siRNAs activity in vivo.
Absent a 50 phosphate, ss-siRNAs were inactive in vitro and
in vivo (Figures 3C, 4B, and 5B). The 50 methylenephophonate
analogs were resistant to dephosphorylation in vivo, and those
exhibiting a conformation and sterioelectronic properties similar
to natural phosphate (e.g., 50-(E)-vinylphosphonate) were more
potent (Figures 5A and 5B). The 50 phosphate was not required
for activities of siRNAs (Figure 4B). Therefore, the loss of
in vitro activity observed for the ss-siRNA without a 50 phosphate
suggests that the 50 phosphate may play an additional role in the
activities of ss-siRNAs.
Discovering Potent and Metabolically Stable ss-siRNAs
In total, the results presented here provide a blueprint for
designing metabolically stable ss-siRNAs capable of activating
the RNAi mechanism in animals (Figure 1A). The 20-F appearsCell 150, 883–894, August 31, 2012 ª2012 Elsevier Inc. 891
to be unique in that it is tolerated and can be positioned
anywhere within the ss-siRNA (Figure 1C). Unfortunately the
ss-siRNAs containing 20-F modifications exhibited poor nucle-
ase stability and may, in part, explain the lack of in vivo activity
reported for ss-siRNAs containing the 20-F (Figure 1C) (Har-
ingsma et al., 2012). Interestingly, these same ss-siRNAs admin-
istered in a lipid formulation were shown to exhibit in vivo activity,
although the authors concluded that the mechanism of action
was not Ago2-mediated degradation of the target mRNA (Har-
ingsma et al., 2012).
The 20-OMe and 20-MOE modifications exhibit greater meta-
bolic stability; however, excessive substitutions within the ss-
siRNA are poorly tolerated (Lima et al., 2009a; Prakash et al.,
2005). Alternating the 20-F and 20-OMe modifications in the
ss-siRNAs enhanced the in vitro potency but required PS substi-
tutions for enhanced metabolic stability (Figures 1A and 1C).
Through the course of these studies, we enhanced the in vitro
potency of the ss-siRNAs 20-fold and metabolical stability to
achieve a tissue half-life of 10 days and duration of action of
7 days in mice (Figures 1A, 6C, and 6D).
Enhancing the Pharmacokinetic Properties of
ss-siRNAs
As demonstrated here, PS modifications can enhance not only
metabolic stability of the ss-siRNA, but also the binding of
oligonucleotides to serum proteins, which is essential to prevent
rapid clearance of the oligonucleotides by glomerular filtration
(Crooke, 2008). Optimal serum protein binding was observed
with oligonucleotides containing >16 PS linkages (Crooke,
2008). Thus, it is not surprising that ss-siRNAs containing 14
PS were more rapidly cleared in vivo, reducing the distribution
to peripheral tissues. Divided doses that reduce peak serum
concentrations and renal clearance enhanced distribution to
the liver somewhat, but adding lipophilic modification like C16
that enhance serum protein binding and cellular uptake was
a better solution (Figures 5B, 5C, and 6F) (Crooke, 2008; Graham
et al., 1998; Graham et al., 2001). These results suggest that
further optimization of the nature and placement of the lipophilic
modification should result in more potent ss-siRNAs.
Implications for RNAi-Based Therapeutics and RNAi
Our results demonstrate that ss-siRNAs function as potent inhib-
itors of gene expression in animals and provide an alternative
strategy for therapeutic gene silencing. ss-siRNAs offer several
advantages over double-stranded RNAs. The need for just one
strand also removes the risk that the passenger strand or its
metabolites might cause undesirable off-target effects. Perhaps
most importantly, double-stranded siRNA therapeutics requires
lipid formulations to achieve useful levels of activity in vivo,
further increasing the complexity and cost of manufacture and
the potential for unanticipated toxicities. By contrast, ss-siRNAs
achieve potent in vivo repression of gene expression using
simple saline dosing solutions. Compared to double-stranded
RNAs or antisense oligonucleotides, little has been done to opti-
mize the activity of ss-siRNAs, and it is expected that further
modification will enhance their value as therapeutics.
An example of the value of this approach is provided by the
companion study in this issue examining allele-selective inhibi-892 Cell 150, 883–894, August 31, 2012 ª2012 Elsevier Inc.tion of huntingtin (HTT) expression (Yu et al., 2012). This study
describes potent and allele-selective silencing. Importantly,
allele-selective inhibition is achieved throughout the brains of
mice following continuous infusion of ss-siRNA, demonstrating
the potential for ss-siRNAs to modulate the expression of key
genes in the central nervous system.
RNAi is almost always associated with duplex RNA. Reports of
active single strands have been confined to assays in cell-free
systems or limited descriptions of relatively inefficient activity
in cells. Our data with ss-siRNAs demonstrate that potent gene
silencing does not require duplex RNA and that the passenger
strand is dispensable. The guide strand alone is sufficient to
form interactions with RISC. Unlike duplex RNA, ss-siRNAs do
require 50 phosphates, identifying one key mechanistic differ-
ence between their actions. Our identification of a stable 50 phos-
phate modification recognizes this difference and provides
a route to efficient silencing in animals.
EXPERIMENTAL PROCEDURES
Synthesis of 50-MP and 50-VP ss-siRNAs
ssRNA were synthesized on ABI 394 synthesizer (1–2 mmol scale) or on
GE Healthcare Bioscience A¨KTA oligopilot synthesizer (40–200 mmol scale)
by the phosphoramidite coupling method on an UnyLinker solid support
(Guzaev and Manoharan, 2003) packed in the column. A 0.1 M solu-
tion of 20-F, 20-O-Me, and 20-O-MOE nucleoside phosphoramidites (1–3;
Extended Experimental Procedures; Figure S1) in anhydrous CH3CN was
used for the synthesis. The 20-O-MOE-5-methyl uridine-50-deoxy-50-methyle-
nephosphonate-30-phosphoramidite (7; Figure S1), 20-O-MOE-5-methyl-
uridine-50-deoxy-50-vinylphosphonate-30-phosphoramidite (8; Figure S1),
20-O-[N-(decanoyl)-6-aminohexyl]-5-methyluridine-30-phosphoramidite (9a;
Figure S1), and 20-O-[N-(hexadecanoyl)-6-aminohexyl]-5-methyluridine-30-
phosphoramidite (9b, please see Figure S1) were dissolved in 40% anhydrous
dichloromethane in anhydrous CH3CN (0.15 M) and used for the synthesis. For
the coupling step, the phosphoramidites were delivered 4- to 6-fold excess
over the loading on the solid support, and phosphoramidite condensation
was carried out for 10 min. A solution of 6% dichloroacetic acid in toluene
was used for removing dimethoxytrityl (DMT) group from the 50 hydroxyl group
of the nucleotide. Extended detritylation condition was used to remove the
DMT group from the secondary hydroxyl group of the UnyLinker solid support.
4,5-Dicyanoimidazole (0.7 M) in anhydrous CH3CN was used as activator
during coupling step. Phosphorothioate linkages were introduced using
0.2M solution of phenylacetyl disulfide in 1:1 pyridine/CH3CN as sulfur transfer
reagent and were treated for 3 min except for the coupling of 50-deoxy-
50methylenephosphonate and 50-deoxy-50-vinylphosphonate phosphorami-
dites (7 and 8; Figure S1); phosphorothioate linkages were introduced using
a solution of 3-((dimethylaminomethylene)amino)-3H-1,2,4-dithiazole-5-thi-
one (0.05 M, DDTT) in 1:1 pyridine/CH3CN and a 3 min contact. Solid-
support-bound ssRNAs were washed with CH2Cl2 and dried under high
vacuum for 4 hr. The ssRNAs were suspended in a solution of iodotrimethylsi-
lane and pyridine in dichloromethane (dissolve 0.75 ml iodotrimethylsilane and
0.53 ml pyridine in 28.2 ml CH2Cl2, use 0.5 ml per mmol of solid support) and
allowed to shake at room temperature for 30 min. Reaction was quenched
with 50% triethylamine in CH3CN containing 1 M 2-mercaptoethanol (0.5 ml
per mmol of solid support). Supernatant was decanted and the solid sup-
port washed with 1:1 triethylamine/CH3CN containing 1 M 2-mercaptoethanol
(2 3 0.5 ml per mmol of solid support). A solution of 1:1 triethylamine/CH3CN
containing 1M 2-mercaptoethanol (0.5 ml per mmol of solid support) was
added and kept at room temperature for 45 min. Supernatant was decanted,
and the residue aqueous ammonia (28–30WT%) containing 1M 2-mercaptoe-
thanol (0.75 ml per mmol of solid support) was added and heated at 55C for
2 hr. The reaction mixture was allowed to come to room temperature and
was kept for an additional 24 hr. The solid support was filtered and washed
thoroughly with water. The filtrate and the washing were combined together
and then cooled in an ice bath and neutralized with glacial acetic acid. Result-
ing colloidal solution was allowed to stand at20C for 2–3 hr. The precipitate
formedwas collected by centrifugation followed by decanting the supernatant.
The precipitated ssRNAs were then dissolved in water and purified by high-
pressure liquid chromatography on a reverse phase column (Waters X-Bridge
C-18 5 mm, 193 250 mm, A = 5mM tributylammonium acetate in 5% aqueous
CH3CN, B = CH3CN, 0 to 90% B in 80 min, flow 7 ml min
-1, l = 260 nm). The
fractions were analyzed by LC-MS, and fractions containing full-length
ssRNAs were pooled together. The tributylammonium counter ions were
exchanged to sodium by high-pressure liquid chromatography on a strong
anion exchange column (GE Healthcare Bioscience, Source 30Q, 30 mm, 2.54
3 8 cm, A = 100 mM ammonium acetate in 30% aqueous CH3CN, B = 1.5 M
NaBr in A, 0%–40% of B in 60 min, flow 14 ml min-1, l = 260 nm). Desalting by
HPLC on a reverse-phase column gave ssRNAs in an isolated yield of 15%–
30% based on the initial loading on the solid support. ssRNAs were character-
ized by ion-pair-HPLC-coupled MS analysis with Agilent 1100 MSD system
(Tables S1 and S2).
Cleavage Activity for Recombinant Human GST-Ago2
Recombinant human Ago2 and 32P-labeled target RNA were prepared as
described elsewhere (Lima et al., 2009b). Ago2 cleavage activity was carried
out as described in Extended Experimental Procedures. The errors reported
for the cleavage activities are based on three trials.
In Vitro Potency of ss-siRNAs and siRNAs in Primary Hepatocytes
In vitro potency of ss-siRNAs and siRNAs was evaluated in primary hepato-
cytes following the protocol described in Extended Experimental Procedures.
In Vitro Potency of ss-siRNA and siRNA in Transfected HeLa Cells
ss-siRNAs were transfected to HeLa cells using Lipofectamine 2000
(see Extended Experimental Procedures). Reduction of target mRNA was
determined by qRT-PCR as previously described (Vickers et al., 2009). Tar-
get mRNA levels were normalized to total RNA using RiboGreen (Life Tech-
nologies). IC50 curves and values were generated using Prism 4 software
(GraphPad,).
In Vivo Activity of ss-siRNA in Mice
Animal experiments were conducted according to American Association for
the Accreditation of Laboratory Animal Care guidelines and were approved
by the Animal Welfare Committee (see Extended Experimental Procedures).
Mice were dosed by single0administration (n = 4) intravenous or subcutaneous
injection, with the exception of subcutaneous doses >50 mg/kg, which con-
sisted of subdivided injections of 25 mg/kg twice a day for the indicated
number of days. Mice were sacrificed 48 hr posttreatment. Liver, kidney,
and spleen weights were taken, and liver tissue was homogenized in guanidine
isothiocyanate (Life Technologies) containing 8% b-mercaptoethanol (Sigma)
immediately following the sacrifice. Reduction of target mRNA expression was
determined by qRT-PCR as previously described (Vickers et al., 2009). Target
mRNA levels were normalized to cyclophilin levels, and values were confirmed
by RiboGreen (see Extended Experimental Procedures).
50-RACE
Male Balb/c mice were subcutaneously injected with 25 mg/kg ssiRNA
every 2 hr for a combined dose of 100mg/kg. Animals were sacrificed 6 hr after
final injection. Liver tissue was homogenized and purified as described
above. RNA ligase-mediated rapid amplification of cDNA ends (50-RACE)
(Life Technologies) was performed on 1 ug of purified total RNA following
manufacturer’s instructions. PCR products were cloned using Topo TA-
Mach1-T1 cells (Life Technologies), as directed by manufacturer’s protocol.
DNA was purified (QIAGEN) from cultured colonies and sequenced.
Determination of ssRNA Liver Concentrations by Hybridization-
Dependent Nuclease ELISA
Levels of ss-siRNAs in the liver of treated animals were determined using
hybridization-dependent nuclease ELISA assay (see Extended Experimental
Procedures).Determination of Tissue Concentrations and Metabolites of ssRNAs
Using LC/MS
ss-siRNAswere extracted from livers and analyzed by liquid-chromatography-
coupled mass spectroscopy analysis (see Extended Experimental Proce-
dures). Mass measurements were made online using a single quadrupole
mass spectrometer scanning 1000–2100 m/z in the negative ionization
mode. Molecular masses were determined using ChemStation analysis pack-
age (Agilent, Santa Clara, CA). Manual evaluation was performed by com-
paring a table of calculatedm/z values corresponding to potential metabolites
with the peaks present in a given spectrum. Peak areas from extracted ion
chromatograms were determined for ssRNAs, 30 N-1 metabolites, and internal
standard (Int. Std.), and a trendline was established using the calibration stan-
dards, plotting concentration of ssRNA against the ratio of the peak areas
ssRNA. Internal standard concentration of ssRNAs and 30 N-1 metabolites
in study samples were determined using established trendlines and were
reported as ug/g tissue.
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